Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 19/20 | 0.62 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4352833 | 0.84 | TRPV1 (0.52) | TRPV1MAPK3 | |
| SCHEMBL14430635 | 0.83 | TRPV1 (0.53) | TRPV1MAPK3 | |
| SCHEMBL4359138 | 0.83 | TRPV1 (0.43) | TRPV1MAPK3HCAR2 | |
| SCHEMBL4076189 | 0.83 | TRPV1 (0.58) | TRPV1MAPK3 | |
| SCHEMBL1860193 | 0.80 | TRPV1 (0.45) | TRPV1MAPK3 | |
| SCHEMBL4355010 | 0.79 | TRPV1 (0.48) | TRPV1MAPK3 | |
| SCHEMBL4362025 | 0.79 | METAP2 (0.41) | TRPV1MAPK3 | |
| SCHEMBL1857454 | 0.79 | TRPV1 (0.42) | TRPV1MAPK3 | |
| SCHEMBL4075406 | 0.78 | TRPV1 (0.46) | TRPV1MAPK3 | |
| SCHEMBL28757821 | 0.78 | TRPV1 (0.50) | TRPV1MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-7488740-B2 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488740-B2 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488740-B2 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| CN-1820008-A | Substituted quinolin-4-ylamine analogues | NEUROGEN CORP (US) | 2006-08-16 | — | — | CN | disclosed |
| EP-1644372-A2 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050070547-A1 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION | 2005-03-31 | — | — | US | disclosed |
| WO-2005007652-A2 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | PIGS, HRH4, GPR52 | TRPV1 279/4885MAPK3 3351/4885HCAR2 34/4885 |
| US-20050070547-A1 | Substituted quinolin-4-ylamine analogues | PIGS, HRH4, GPR52 | TRPV1 281/4885MAPK3 3441/4885HCAR2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.